Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.

@article{Reese2012PharmacoeconomicCO,
  title={Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.},
  author={Jens Peter Reese and J. Rickie Dams and Yaroslav Winter and Monika Balzer-Geldsetzer and Wolfgang Hermann Oertel and Richard C. Dodel},
  journal={Expert opinion on pharmacotherapy},
  year={2012},
  volume={13 7},
  pages={939-58}
}
INTRODUCTION Parkinson's disease (PD) is one of the most common neurodegenerative diseases. In the later (advanced) stages of PD, the initial treatment of early PD becomes less effective and long-term side effects of dopaminergic treatment become apparent. In advanced PD, motor and non-motor complications occur, which increase treatment costs. Increasing disability and impaired activities of daily living concomitantly raise indirect costs, due to loss in productivity. Hence, the economic burden… CONTINUE READING